TNF-alpha and insulin-resistance: Metabolic effects of in vivo therapeutic blockade;TNF-alfa e insulino-resistenza: Effetti metabolici del blocco terapeutico in vivo

Reumatismo

Volumn 61, Issue 4, 2009, Pages 254-259

  Ursini, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Diabetes; Infliximab; Insulin resistance; TNF alpha

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; INSULIN; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

GOLD STANDARD; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; MEDICAL LITERATURE; METABOLISM; PATHOGENESIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; HUMANS; INSULIN RESISTANCE; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749118556     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
2. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumor necrosis-alpha converting enzyme in psoriasis. British Journal of Dermatology 2005; 152: 915-9.
3. Xu H, Sethi JK, Hotamisligil GS. Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1. J Biol Chem 1999; 274: 262879-95.
4. Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics 2002; 2: 215-21.
5. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004; 63: 755-8.
6. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004; 4: 449-59.
7. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 2002; 1: 175: 323-9.
8. Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel 2001; 4: 635-50.
9. Sethi J, Hotamisligil GS. The role of TNFα in adipocyte metabolism. Semin Cell Dev Biol 1999; 10: 19-29. 10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
10. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-9.
11. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-9.
12. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
13. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-9.
14. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 15; 97: 1111-6.
15. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-10.
16. Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K. Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 1998; 41: 860-1.
17. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alphaand obesity-induced insulin resistance. Science 1996; 271: 665.8.
18. Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996; 271: 9895-7.
19. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 2000; 275: 9047-54.
20. REMICADE® (infliximab) product monograph. Centocor, Inc., Malvern, PA 19355, USA, 2001.
21. Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 2004; 4: 437-47, ix.
22. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
23. Nestorov I. Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum 2005; 34 (5 Pt 2): 12-8.
24. Borai A, Livingstone C, Ferns GA. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007; 44: 324-42.
25. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 1979; 237: E214-E223.
26. Laakso M. How good a marker is insulin level for insulin resistance. Am J Epidemiol 1993; 137: 959-65.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
28. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 4426-33.
29. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
30. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
31. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, Baron AD. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001; 86: 5457-64.
32. Rabasa-Lhoret R, Bastard JP, Jan V, Ducluzeau PH, Andreelli F, Guebre F, et al. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin resistant states. J Clin Endocrinol Metab 2003; 88: 4917-23.
33. Skrha J, Haas T, Sindelka G, Prazny M, Widimsky J, Cibula D, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004; 89: 135-41.
34. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab. 2004; 89: 1481-4.
35. Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004; 34: 41-2.
36. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
37. Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol 2008; 35: 355-7.
38. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 2007; 62: 218-22.
39. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
40. Huvers FC, Popa C, Netea MG, van den Hoogen FH, Tack CJ. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007; 66: 558-9.